Federated Hermes Inc. Sells 54,824 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Federated Hermes Inc. decreased its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 196,536 shares of the company’s stock after selling 54,824 shares during the quarter. Federated Hermes Inc. owned about 0.39% of ALX Oncology worth $2,926,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after acquiring an additional 4,706 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of ALX Oncology during the third quarter worth $168,000. SG Americas Securities LLC boosted its position in shares of ALX Oncology by 201.4% during the fourth quarter. SG Americas Securities LLC now owns 30,348 shares of the company’s stock worth $452,000 after acquiring an additional 20,279 shares during the last quarter. Barclays PLC raised its stake in ALX Oncology by 57.1% during the third quarter. Barclays PLC now owns 26,964 shares of the company’s stock valued at $129,000 after purchasing an additional 9,796 shares in the last quarter. Finally, Forefront Analytics LLC purchased a new stake in ALX Oncology during the third quarter valued at $66,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Trading Down 0.1 %

Shares of ALXO opened at $16.86 on Friday. ALX Oncology Holdings Inc. has a twelve month low of $3.94 and a twelve month high of $17.42. The company has a market cap of $843 million, a P/E ratio of -4.50 and a beta of 1.58. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $13.63 and its 200-day simple moving average is $12.29.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, analysts expect that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Analyst Upgrades and Downgrades

ALXO has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a research note on Wednesday, April 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.83.

Insider Activity

In other news, CEO Jason Lettmann bought 4,400 shares of ALX Oncology stock in a transaction dated Thursday, March 14th. The shares were acquired at an average price of $11.31 per share, with a total value of $49,764.00. Following the completion of the purchase, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Jason Lettmann bought 4,400 shares of ALX Oncology stock in a transaction dated Thursday, March 14th. The shares were acquired at an average price of $11.31 per share, with a total value of $49,764.00. Following the completion of the purchase, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now directly owns 628,359 shares in the company, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. Insiders own 50.30% of the company’s stock.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.